Unbound MEDLINE

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.

Abstract

OBJECTIVE
To summarize and evaluate the published literature pertaining to boceprevir and telaprevir, and to provide clinicians with suggestions for use in patients with chronic hepatitis C infection.
METHODS
A standardized search strategy was performed using the MEDLINE, EMBASE, Google Scholar and International Pharmaceuticals Abstracts databases using the search terms "boceprevir", "telaprevir", "boceprevir and hepatitis C", and "telaprevir and hepatitis C". A manual search of references was performed to identify articles missed by the electronic search. Studies were included in the review if they assessed either boceprevir or telaprevir in comparison with standard of care in chronic hepatitis C patients.
RESULTS
The studies identified assessed boceprevir and telaprevir in genotype-1 hepatitis C patients. In both treatment-naive and treatment-experienced patients, sustained virological response rates were achieved more often with boceprevir or telaprevir in combination with pegylated interferon and ribavirin compared with pegylated interferon and ribavirin alone. Both medications were well tolerated, with anemia presenting as the most treatment-limiting adverse effect.
CONCLUSIONS
Boceprevir and telaprevir will revolutionize the management of hepatitis C genotype 1 patients and will most likely decrease the burden of end-stage disease worldwide. However, current clinical limitations include establishing appropriate and cost-effective treatment durations, and use in special populations such as transplant patients and patients coinfected with HIV. Future research will need to clarify these clinical obstacles to clearly define the role of these agents in hepatitis C management.

Links

  • PMC Free PDF
  • Publisher Full Text
  • Authors

    Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM

    Institution

    University of British Columbia, BC, Canada.

    Source

    Canadian journal of gastroenterology = Journal canadien de gastroenterologie 26:4 2012 Apr pg 205-10

    MeSH

    Antiviral Agents
    Disease Management
    Disease Progression
    Drug Interactions
    Drug Therapy, Combination
    Genome, Viral
    Hepacivirus
    Hepatitis C, Chronic
    Humans
    Interferon-alpha
    Oligopeptides
    Polyethylene Glycols
    Proline
    Recombinant Proteins
    Ribavirin
    Standard of Care
    Treatment Outcome
    Viral Load

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    22506260